Talzenna bags EU approval for gBRCA-mutated breast cancer

An important milestone in breast cancer treatment has been reached as the European Commission announced the approval of Pfizer’s Talzenna for patients with inherited BRCA-mutated locally advanced or metastatic breast cancer.

To learn more about this important approval, click the link below:


Share This Article